CYP3A4 and metabolic dysfunction-associated steatohepatitis: Alterations in CYP3A4, which plays a role in the metabolism for about half of clinically applicable drugs, has the potential to drive variable drug response in patients with NAFLD and NASH, further complicating treatment strategies for patients with metabolic disease41.